Have you managed a patient on an unboosted INSTI with an enzyme inducer?
We’re collecting real-world clinical cases to better understand drug interactions between unboosted integrase inhibitors (such as dolutegravir or bictegravir) and enzyme inducers (including rifampicin or carbamazepine).
Your experience could contribute to safer prescribing and help shape clinical practice.
Clinical Outcome: Co-administration of Tenofovir-DF (TDF) and Diclofenac can cause nephrotoxicity.
Chronic diclofenac use in a patient on TDF led to acute kidney injury. Diclofenac inhibits MRP4, increasing TDF renal exposure. Switching to TAF or close monitoring can reduce nephrotoxicity risk.
Report a case and increase your chances of winning a grant to attend the congress of your choice in 2026. Remember, the more cases you report, the higher your chances of winning the prize!
Interested in a specific drug combination for interactions? Check all cases!
